Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High‐Dose Intravenous Administration in Young Children With Benzodiazepine‐Refractory Status Epilepticus
| Autor: | Richard C. Brundage, Vijay Ivaturi, James M. Chamberlain, Shlomo Shinnar, Hannah R. Cock, Lynn Babcock, Jaideep Kapur, Nathan B. Fountain, James C. Cloyd, Lisa D. Coles, Robert Silbergleit, Usha Mishra, Jordan J. Elm, Daniel H. Lowenstein, Abhishek G. Sathe |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Phenytoin Levetiracetam medicine.drug_class Status epilepticus 030226 pharmacology & pharmacy Article Benzodiazepines 03 medical and health sciences Status Epilepticus 0302 clinical medicine Fosphenytoin Humans Medicine Pharmacology (medical) Child Infusions Intravenous Pharmacology Valproic Acid Benzodiazepine Dose-Response Relationship Drug business.industry Free fraction Child Preschool 030220 oncology & carcinogenesis Anesthesia Anticonvulsants Female lipids (amino acids peptides and proteins) medicine.symptom business Protein Binding medicine.drug Blood sampling |
| Zdroj: | J Clin Pharmacol |
| ISSN: | 1552-4604 0091-2700 |
| DOI: | 10.1002/jcph.1801 |
| Popis: | Fosphenytoin (FOS) and its active form, phenytoin (PHT), levetiracetam (LEV), and valproic acid (VPA) are commonly used second-line treatments of status epilepticus. However, limited information is available regarding LEV and VPA concentrations following high intravenous doses particularly in young children. The Established Status Epilepticus Treatment Trial (ESETT), a blinded, comparative effectiveness study of FOS, LEV, and VPA for benzodiazepine-refractory status epilepticus provided an opportunity to investigate early drug concentrations. Patients ≥ 2 years who continued to seizure despite receiving adequate doses of benzodiazepines were randomized to FOS, LEV or VPA infused over 10 minutes. A sparse blood sampling approach was used, with up to two samples collected per patient within two hours following drug administration. The objective of this work was to report early drug exposure of PHT, LEV and VPA and plasma protein binding of PHT and VPA. Twenty-seven children with median (interquartile range) age of 4 (2.5, 6.5) years were enrolled. The total plasma concentrations ranged from 69-151.3 μg/mL for LEV, 11.3-26.7 μg/mL for PHT and 126-223 μg/mL for VPA. Free fraction ranged from 4-19% for PHT and 17-51% for VPA. This is the first report in young children of LEV concentrations with convulsive status epilepticus as well as VPA concentrations after a 40 mg/kg dose. Several challenges limited patient enrollment and blood sampling. Additional studies with a larger sample size are required to evaluate the exposure-response relationships in this emergent condition. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text